82 results
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
12 Mar 24
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
7:15am
million for the full year of 2023, compared to $375,000 for 2022.
Research and Development (R&D) Expenses: R&D expenses were $9.9 million for the fourth … December 31,
Year ended December 31,
Revenues
Product revenues
Operating expenses
Cost of goods sold
Research and development
Selling, general
8-K
EX-10.1
BTAI
BioXcel Therapeutics Inc
8 Feb 24
Other Events
4:53pm
be included in BXCL 701 Primary Disposition Proceeds, except to the extent such proceeds were used for research and development activities for oncology … and Development Activities” means, with respect to any Product, any combination of research, development, manufacture, import, use, sale, licensing, importation
8-K
lhlvm bw2feanyc8k
12 Dec 23
Other Events
7:00am
8-K
EX-99.1
h77ev3nx4u6i3e
14 Nov 23
Results of Operations and Financial Condition
12:00am
8-K
EX-99.2
equg35ibn3a0k1ef
10 Oct 23
Regulation FD Disclosure
7:06am
8-K
EX-10.1
6gmupv6h5v
25 Sep 23
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-99.1
0kzzvr
14 Aug 23
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
7:20am
8-K
EX-99.1
biz63cmkrp5
8 May 23
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
8:30am
8-K
EX-99.1
dh4qyf
10 Nov 22
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
7:15am